현재 위치
Home
Original Article
Tyrosine Kinase 억제제와의 약물 상호작용이 약물 혈중농도 변화에 따라 부작 용 발생에 미치는 영향 : 메타분석 연구
The Impact of Drug Interactions with Tyrosine Kinase Inhibitors on Adverse Event Development based on the changes of drug concentration level : Meta- analysis
-
- 발행기관
- 한국임상약학회 바로가기
-
- 간행물
- 한국임상약학회지 KCI 등재 바로가기
-
- 통권
- 제34권 제1호 (2024.03)바로가기
-
- 페이지
- pp.71-78
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A444118
※ 기관로그인 시 무료 이용이 가능합니다.
4,000원
원문정보
초록
- 영어
- Background: Oral cancer drugs, particularly tyrosine kinase inhibitors (TKIs), are increasingly popular due to their convenience. However, they pose challenges like drug interactions, especially with medications like azole antifungals. While the FDA provides some guidance, more detailed information is needed to manage these interactions effectively. A meta-analysis was conducted to understand the impact of interactions between TKIs and azole antifungals on adverse events during clinical studies. Methods: A meta-analysis followed PRISMA guidelines. Data from PubMed, EMBASE, and references were searched until November 30, 2021. Inclusion criteria encompassed studies on TKI-antifungal interactions in English. Study selection and quality assessment were conducted by two independent investigators. Results: Out of 158 articles, 11 were selected for analysis. Combination therapy showed a slight increase in adverse events but was not statistically significant (OR 1.02, 95% CI 0.49-2.13, p=0.95). AUC and Cmax fold changes did not significantly impact adverse event development. Both itraconazole and ketoconazole showed no significant difference in adverse event development compared to TKI alone. Conclusions: Study finds TKI-DDI not significantly linked to AE increase; azole antifungal types not related to AE. Future DDI research crucial for drug development.
목차
ABSTRACT
Materials and Methods
Data Sources and Search Strategy
Study Selection
Data Extraction and Quality Assessment
Data Synthesis and Analysis
Results
Study Selection
Study Description
Overall adverse events development
Adverse event development according to AUC fold change levels
Adverse event development according to Cmax fold change levels
Adverse event development according to the types ofantifungals
Discussion
Conclusion
Conflict of Interest
References
키워드
Antifungal agents drug interactions meta-analysis tyrosine kinase inhibitors저자
간행물 정보
발행기관
-
- 발행기관명
- 한국임상약학회 [Korean College of Clinical Pharmacy]
- 설립연도
- 1
- 분야
- 의약학>약학
- 소개
- 합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.
간행물
-
- 간행물명
- 한국임상약학회지 [Korean Journal of Clinical Pharmacy]
- 간기
- 계간
- pISSN
- 1226-6051
- 수록기간
- 1991~2026
- 등재여부
- KCI 등재
- 십진분류
- KDC 518 DDC 615
이 권호 내 다른 논문 / 한국임상약학회지 제34권 제1호
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.